卡博特(CBT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CBT 卡博特

盘前交易 07-31 04:54:54 EDT

88.23

-3.30

-3.61%

最高89.08	最低85.77	成交量59.62万
今开87.03	昨收91.53	日振幅3.62%
总市值45.55亿	流通市值44.93亿	总股本5,162万
成交额5,234万	换手率1.17%	流通股本5,093万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CBT","market":"US","secType":"STK","nameCN":"卡博特","latestPrice":88.23,"timestamp":1785441600000,"preClose":91.53,"halted":0,"volume":596174,"delay":0,"changeRate":-0.036053752867912126,"floatShares":50928400,"shares":51621417,"eps":5.293621,"marketStatus":"盘前交易","change":-3.3,"latestTime":"07-31 04:54:54 EDT","open":87.03,"high":89.08,"low":85.768,"amount":52344035.46782,"amplitude":0.036185,"askPrice":96.47,"askSize":100,"bidPrice":74.38,"bidSize":100,"shortable":3,"etf":0,"ttmEps":5.293621,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785504600000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":88.23,"dividendRate":0.020401,"postHourTrading":{"tag":"盘后","latestPrice":88.23,"preClose":88.23,"latestTime":"19:34 EDT","volume":36007,"amount":3177117.83,"timestamp":1785454447180,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.025253931575839,"impliedVol":0.4241,"impliedVolPercentile":0.972},"requestUrl":"/m/hq/s/CBT","defaultTab":"news","newsList":[{"id":"1149145238","title":"财报前瞻｜卡博特本季度营收预计同比降2.47%，机构观点偏中性","url":"https://stock-news.laohu8.com/highlight/detail?id=1149145238","media":"财报Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149145238?lang=zh_cn&edition=full","pubTime":"2026-07-27 09:40","pubTimestamp":1785116459,"startTime":"0","endTime":"0","summary":"卡博特将于2026年08月03日发布新一季财报，市场关注盈利韧性与费用节奏对利润率的影响。市场一致预期显示，本季度卡博特营收约为9.31亿美元，同比下降2.47%；调整后每股收益约为1.66美元，同比下降9.13%；息税前利润约为1.45亿美元，同比下降11.08%。上季度卡博特营收9.04亿美元，同比下降3.42%；毛利率24.00%；归属于母公司股东的净利润6,800.00万美元，净利率7.52%；调整后每股收益1.61美元，同比下降15.26%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜卡博特本季度营收预计同比降2.47%，机构观点偏中性","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652140205","title":"拨康视云-B(02592)：美国药管局完成对CBT-358新药临床试验申请的安全性审查","url":"https://stock-news.laohu8.com/highlight/detail?id=2652140205","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652140205?lang=zh_cn&edition=full","pubTime":"2026-07-17 18:40","pubTimestamp":1784284833,"startTime":"0","endTime":"0","summary":"智通财经APP讯，拨康视云-B 发布公告，于2026年7月14日，已完成有关于2026年5月21日向美国食品及药物管理局提交的CBT-358新药临床试验申请的审查期。美国药管局已完成对新药临床试验申请的安全性审查，并对拟议进行的临床研究不持异议。透过结合这两种成分，CBT-358有望治疗因泪液分泌不足所引起的干眼症，提升舒适度。本公司认为，由于美国药管局已完成对CBT-358的安全性审查，标志着CBT-358临床开发的关键里程碑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469135.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02592","BMED","IBBQ","CBT","BK1161","BK4090"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640864150","title":"拨康视云-B：核心产品CBT-001临床试验达重要里程碑，有望成全球首个翼状胬肉治疗药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2640864150","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640864150?lang=zh_cn&edition=full","pubTime":"2026-06-04 20:28","pubTimestamp":1780576080,"startTime":"0","endTime":"0","summary":"6月4日，拨康视云-B（02592）发布公告，其核心产品CBT-001的最后一名患者已完成为期12个月的终点访视，并于此次访视中进行了对CBT-001主要疗效终点（翼状胬肉病变缩小程度及眼部不适症状评分）在第3期多地区临床试验（“多地区临床试验”）中的评估。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606043760601811.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606043760601811.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","02592","CBT","BK4090"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640161151","title":"拨康视云-B(02592)完成CBT-001最后一次为期12个月的终点访视","url":"https://stock-news.laohu8.com/highlight/detail?id=2640161151","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640161151?lang=zh_cn&edition=full","pubTime":"2026-06-04 18:49","pubTimestamp":1780570172,"startTime":"0","endTime":"0","summary":"智通财经APP讯，拨康视云-B 发布公告，最后一名患者已完成为期12个月的访视，并于此次访视中进行了对CBT-001主要疗效终点在第3期多地区临床试验中的评估。CBT-001为本集团核心产品之一。CBT-001又称尼达尼布游离硷，是一种局部眼用滴眼液乳液，目前正进行第3期多地区临床试验研究。本公司认为，完成最后一次为期12个月的终点访视是CBT-001开发过程中的重要里程碑，此举将使本公司得以在2026年第三季度公布12个月疗效的初步数据。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450258.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CBT","02592","BK4090","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637348383","title":"拨康视云-B(02592)：就CBT-358提交新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2637348383","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637348383?lang=zh_cn&edition=full","pubTime":"2026-05-22 22:37","pubTimestamp":1779460627,"startTime":"0","endTime":"0","summary":"智通财经APP讯，拨康视云-B 发布公告，于2026年5月21日，集团向美国食品及药物管理局提交有关CBT-358的新药临床试验申请。因此，CBT-358 有可能同时解决水液缺乏型及过度蒸发型干眼症，两者为多数干眼症的根本成因。基于该项极具前景的突破，该公司已加速 CBT-358 的开发进程，并较预期更早地成功完成支持新药临床试验申请的研究。提交新药临床试验申请为美国药管局启动药物审查程序以及取得监管批准以展开CBT-358的临床试验的第一步。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445357.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02592","CBT","BK4090"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186610359","title":"卡博特宣布扩张计划与最新动态，备受期待的不列颠哥伦比亚省首秀在即","url":"https://stock-news.laohu8.com/highlight/detail?id=1186610359","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186610359?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:13","pubTimestamp":1778156036,"startTime":"0","endTime":"0","summary":"卡博特雷夫尔斯托克项目正式公布了其扩张蓝图与一系列进展，为其即将到来的不列颠哥伦比亚省首次亮相做足准备。此次披露的信息为该高端度假项目的盛大启幕增添了更多看点，预示着其在该地区旅游地产市场的雄心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBT","BK4090"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631686436","title":"拨康视云-B(02592)：美国药管局已完成对CBT-199的安全性审查","url":"https://stock-news.laohu8.com/highlight/detail?id=2631686436","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631686436?lang=zh_cn&edition=full","pubTime":"2026-04-30 16:41","pubTimestamp":1777538474,"startTime":"0","endTime":"0","summary":"智通财经APP讯，拨康视云-B 发布公告，本公司于美利坚合众国(美国)特拉华州注册成立的全资附属公司 ADS Therapeutics LLC ，已完成有关于2025年12月12日向美国食品及药物管理局提交的CBT-199新药临床试验申请的审查期。美国药管局已完成对新药临床试验申请的安全性审查，而美国药管局的结论为本公司可推进拟议的临床研究。本公司认为，由于美国药管局已完成对CBT-199的安全性审查，标志着CBT-199临床开发的关键里程碑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437209.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CBT","BK1161","02592","BK4090"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1192993327","title":"财报前瞻｜卡博特本季度营收预计降12.10%，EPS或承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1192993327","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192993327?lang=zh_cn&edition=full","pubTime":"2026-04-28 12:39","pubTimestamp":1777351163,"startTime":"0","endTime":"0","summary":"卡博特将于2026年05月05日公布新一季度财报，市场预计营收与盈利同比走弱，关注成本传导与下游需求恢复节奏。依据一致预期，本季度卡博特营收约为9.00亿美元，调整后每股收益约为1.46美元；公司层面未披露本季度毛利率及净利润或净利率的明确指引，公开预期中也暂未提供相应口径，故不展示相关预测。在2026年01月01日至2026年04月28日期间，未检索到覆盖卡博特本季度财报的明确机构前瞻与多空比例统计，无法给出看多或看空的占比结论。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜卡博特本季度营收预计降12.10%，EPS或承压","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620420690","title":"港股异动 | 拨康视云-B(02592)跌超6%创新低 宣布撤回CBT-009新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2620420690","media":"智通财经","labels":["executive","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620420690?lang=zh_cn&edition=full","pubTime":"2026-03-20 10:35","pubTimestamp":1773974109,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，拨康视云-B跌超6%，低见1.82港元刷新上市以来新低。在提交新药临床试验申请后，药审中心批准了一款可比药品在中国上市。经后续与药审中心沟通后，公司相信由于各区域监管要求不同，将中国纳入多地区临床试验可能存在困难。为避免后续研发风险，及更好地分配集团的资源，公司已决定主动就可能于中国进行的第三期试验撤回现有的新药临床试验申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416373.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02592","BK4090","VXUS","BK4588","BK4585","CBT","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620244220","title":"拨康视云-B(02592)：撤回CBT-009新药临床试验申请 重新评估临床开发策略","url":"https://stock-news.laohu8.com/highlight/detail?id=2620244220","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620244220?lang=zh_cn&edition=full","pubTime":"2026-03-19 19:05","pubTimestamp":1773918320,"startTime":"0","endTime":"0","summary":"在提交新药临床试验申请后，药审中心批准了一款可比药品在中国上市。经后续与药审中心沟通后，公司相信由于各区域监管要求不同，将中国纳入多地区临床试验可能存在困难。为避免后续研发风险，及更好地分配集团的资源，公司已决定主动就可能于中国进行的第三期试验撤回现有的新药临床试验申请。待完成相关补充研究或调整临床试验方案后，公司将根据情况再次与药审中心进行临床试验申请前咨询会议或重新提交临床试验申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416056.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02592","CBT","BK4090"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611615103","title":"拨康视云-B(02592)：CBT-199新药临床试验申请已生效，临床试验被认定为可安全推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2611615103","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611615103?lang=zh_cn&edition=full","pubTime":"2026-02-16 12:45","pubTimestamp":1771217106,"startTime":"0","endTime":"0","summary":"由于美国药管局未发出任何临床试验暂停令，新药临床试验申请现已生效，临床试验被认定为可安全推进。CBT-199已自2023年6月起于临床前动物研究中进行安全性和耐受性评估，有关研究预期将有助于未来的临床试验。本公司认为，由于CBT-199的临床试验现被认为可安全推进，标志着CBT-199临床开发的关键里程碑，且本集团已正式获授权启动第2阶段临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1405684.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02592","BK1161","BK4090","CBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157866407","title":"卡博特公司董事会宣布派发季度股息","url":"https://stock-news.laohu8.com/highlight/detail?id=1157866407","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157866407?lang=zh_cn&edition=full","pubTime":"2026-02-03 05:34","pubTimestamp":1770068084,"startTime":"0","endTime":"0","summary":"2026年2月2日，波士顿——卡博特公司董事会于2026年1月9日（星期五）宣布，将向公司所有流通在外的普通股派发每股0.45美元的季度股息。此次股息将于2026年3月13日支付给在2026年2月27日营业时间结束时登记在册的股东。卡博特公司是一家全球性的特种化学品和高性能材料企业，总部位于马萨诸塞州波士顿。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBT","BK4090"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183799657","title":"卡博特公司完成从普利司通收购墨西哥碳素制造公司","url":"https://stock-news.laohu8.com/highlight/detail?id=1183799657","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183799657?lang=zh_cn&edition=full","pubTime":"2026-02-02 22:01","pubTimestamp":1770040897,"startTime":"0","endTime":"0","summary":"卡博特公司（CBT）已正式完成对墨西哥碳素制造公司（Mexico Carbon Manufacturing S.a. De C.v.）的收购，该资产此前隶属于普利司通公司。此项交易的达成，标志着卡博特在全球碳素材料市场的战略布局进一步深化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBT","BK4090"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516639606","title":"卡博特盘中异动 下午盘快速跳水5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516639606","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516639606?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:24","pubTimestamp":1741033499,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时24分，卡博特股票出现异动，股价急速跳水5.16%。截至发稿，该股报81.56美元/股，成交量20.8442万股，换手率0.38%，振幅5.24%。机构评级方面，在所有5家参与评级的机构中，40%的券商给予买入建议，40%的券商给予持有建议，20%的券商给予卖出建议。卡博特股票所在的化学制品行业中，整体跌幅为0.26%。卡博特公司简介：卡博特公司生产和销售各种化学品、材料和化学制品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304042459abe69504&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304042459abe69504&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4090","CBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509849523","title":"卡博特盘中异动 下午盘急速上涨5.01%报89.12美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509849523","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509849523?lang=zh_cn&edition=full","pubTime":"2025-02-05 03:54","pubTimestamp":1738698897,"startTime":"0","endTime":"0","summary":"北京时间2025年02月05日03时54分，卡博特股票出现波动，股价大幅上涨5.01%。截至发稿，该股报89.12美元/股，成交量44.7142万股，换手率0.82%，振幅5.61%。机构评级方面，在所有5家参与评级的机构中，40%的券商给予买入建议，40%的券商给予持有建议，20%的券商给予卖出建议。卡博特股票所在的化学制品行业中，整体涨幅为1.69%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020503545796180984&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020503545796180984&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CBT","BK4090"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172882719","title":"卡博特2025年第一季度每股盈利$1.76，超出$1.74预期，销售额$9.55亿未达$9.971亿预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1172882719","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172882719?lang=zh_cn&edition=full","pubTime":"2025-02-04 05:40","pubTimestamp":1738618816,"startTime":"0","endTime":"0","summary":"卡博特报告季度每股收益为1.76美元，超出分析师一致预期的1.74美元，增幅为1.15%。公司季度销售额为9.55亿美元，未达到分析师一致预期的9.971亿美元，差距为4.22%。与上年同期的9.58亿美元销售额相比，下降了0.31%。以上内容来自Benzinga Earnings专栏，原文如下：Cabot  reported quarterly earnings of $1.76 per share which beat the analyst consensus estimate of $1.74 by 1.15 percent. This is a 12.82 percent increase over earnings of $1.56 per share from the same period last year.  The company reported quarterly sales of $955.00 million which missed the analyst consensus estimate of $997.10 million by 4.22 per","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"卡博特2025年第一季度每股盈利$1.76，超出$1.74预期，销售额$9.55亿未达$9.971亿预期","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2492997934","title":"卡博特跌1.87% 股价跌破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2492997934","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492997934?lang=zh_cn&edition=full","pubTime":"2024-12-18 04:02","pubTimestamp":1734465764,"startTime":"0","endTime":"0","summary":"北京时间2024年12月18日04时02分，卡博特股票出现异动，股价急速跳水1.87%。截至发稿，该股报100.00美元/股，成交量13.0983万股，换手率0.24%，振幅1.71%。机构评级方面，在所有5家参与评级的机构中，40%的券商给予买入建议，40%的券商给予持有建议，20%的券商给予卖出建议。卡博特股票所在的化学制品行业中，整体涨幅为0.06%。卡博特公司简介：卡博特公司生产和销售各种化学品、材料和化学制品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218040245a1f699a9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218040245a1f699a9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CBT","BK4090"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2482427927","title":"卡博特2024财年实现净利润3.80亿美元，同比减少13.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482427927","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482427927?lang=zh_cn&edition=full","pubTime":"2024-11-10 00:02","pubTimestamp":1731168165,"startTime":"0","endTime":"0","summary":"11月10日，卡博特公布财报，公告显示公司2024财年净利润为3.80亿美元，同比减少13.04%；其中营业收入为39.94亿美元，同比增加1.60%，每股基本收益为--。从资产负债表来看，卡博特总负债21.46亿美元，其中短期债务53.00百万美元，资产负债比为1.75，流动比率为2.08。机构评级：截至2024年11月10日，当前有5家机构对卡博特目标价做出预测，其中目标均价为116.60美元，其中最低目标价为105.00美元，最高目标价为127.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241110000317abb10131&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241110000317abb10131&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2481856989","title":"卡博特盘中异动 早盘股价大涨5.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481856989","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481856989?lang=zh_cn&edition=full","pubTime":"2024-11-06 22:38","pubTimestamp":1730903931,"startTime":"0","endTime":"0","summary":"北京时间2024年11月06日22时38分，卡博特股票出现波动，股价急速拉升5.82%。截至发稿，该股报115.20美元/股，成交量3.5638万股，换手率0.07%，振幅1.78%。卡博特股票所在的化学制品行业中，整体涨幅为0.40%。其相关个股中，Avient Corporation、Orion S.A.、英诺斯派材料涨幅较大，Gevo, Inc.、Crown Electrokinetics Corp.、中北能较为活跃，换手率分别为1.07%、0.55%、0.39%，振幅较大的相关个股有哈德森科技、Gevo, Inc.、Avient Corporation，振幅分别为8.43%、5.96%、5.51%。卡博特公司简介：Cabot Corp 生产和销售各种化学品、材料和化学制品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110622385295bddd86&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110622385295bddd86&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4090","CBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2481047665","title":"抑郁症的电子丧钟，响了","url":"https://stock-news.laohu8.com/highlight/detail?id=2481047665","media":"虎嗅网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481047665?lang=zh_cn&edition=full","pubTime":"2024-11-06 07:12","pubTimestamp":1730848336,"startTime":"0","endTime":"0","summary":"“原来抑郁症会死人。”AI颠覆心理咨询，来势凶猛抑郁症、焦虑症、PUA、NPD，回避型依恋人格等曾经生僻的词汇，在心理压力越来越大的今天，越来越为大众所熟知了。号称世界第一的心理个评估工具“Limbic Access”，已经为全球超26万人提供了服务。经过短短3年的发展，“小天”的用户数量已经超过了10万。某全球知名社交平台引入的AI，通过语言预测精神分裂等精神疾病发作的准确率也达到83%。前述业内人士表示。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8eHT7BAImoT","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"ifeng_tech","symbols":["BK4573","LU0127658192.USD","BK4566","LU0170899867.USD","LU0215105999.USD","LU0130517989.USD","LU0187121727.USD","BK4592","BK4077","BK4579","BK4533","BK4574","IE00BJTD4N35.SGD","LU0154236417.USD","BK4534","IE00BKVL7J92.USD","IE00BWXC8680.SGD","LU0109391861.USD","LU0048573561.USD","LU0106261372.USD","BK4576","LU0006306889.USD","BK4090","LU0052756011.USD","BK4585","LU0234570918.USD","BK4538","IE00BKPKM429.USD","LU0130102774.USD","LU0096364046.USD","IE00BJTD4V19.USD","LU0056508442.USD","IE0004091025.USD","LU0029864427.USD","IE00BSNM7G36.USD","BK4581","LU0061474705.USD","IE0034235303.USD","IE0034235188.USD","LU0080751232.USD","LU0158827948.USD","CBT","LU0128525929.USD","LU0130518102.USD","IE00BK4W5M84.HKD","LU0061475181.USD","IE00BK4W5L77.USD","LU0097036916.USD","LU0128525689.USD"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.cabotcorp.com","stockEarnings":[{"period":"1week","weight":-0.0099},{"period":"1month","weight":-0.0285},{"period":"3month","weight":0.141},{"period":"6month","weight":0.2222},{"period":"1year","weight":0.2183},{"period":"ytd","weight":0.3312}],"compareEarnings":[{"period":"1week","weight":0.0048},{"period":"1month","weight":-0.0068},{"period":"3month","weight":0.0292},{"period":"6month","weight":0.0719},{"period":"1year","weight":0.169},{"period":"ytd","weight":0.0876}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Cabot Corporation业务初始于1882年，于1960年在特拉华州注册成立。该公司是一家全球特种化学品和性能材料公司，总部位于马萨诸塞州波士顿。公司主要产品为增强和特种碳、特种化合物、导电添加剂、碳纳米管、气相金属氧化物、喷墨着色剂和气凝胶。","yearOnYearQuotes":[{"month":1,"riseRate":0.434783,"avgChangeRate":0.012443},{"month":2,"riseRate":0.565217,"avgChangeRate":0.030841},{"month":3,"riseRate":0.608696,"avgChangeRate":0.019173},{"month":4,"riseRate":0.553191,"avgChangeRate":0.019336},{"month":5,"riseRate":0.446809,"avgChangeRate":0.004076},{"month":6,"riseRate":0.468085,"avgChangeRate":0.000401},{"month":7,"riseRate":0.489362,"avgChangeRate":0.018101},{"month":8,"riseRate":0.456522,"avgChangeRate":0.000293},{"month":9,"riseRate":0.478261,"avgChangeRate":-0.000003},{"month":10,"riseRate":0.456522,"avgChangeRate":-0.01138},{"month":11,"riseRate":0.673913,"avgChangeRate":0.018365},{"month":12,"riseRate":0.608696,"avgChangeRate":0.00955}],"exchange":"NYSE","name":"卡博特","nameEN":"Cabot"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"卡博特(CBT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供卡博特(CBT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"卡博特,CBT,卡博特股票,卡博特股票老虎,卡博特股票老虎国际,卡博特行情,卡博特股票行情,卡博特股价,卡博特股市,卡博特股票价格,卡博特股票交易,卡博特股票购买,卡博特股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"卡博特(CBT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供卡博特(CBT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}